Journal article
Potential role of abciximab in ischemic cerebrovascular disease
The American journal of cardiology, Vol.85(8), pp.47-51
2000
DOI: 10.1016/S0002-9149(00)00878-X
PMID: 10793180
Abstract
Abciximab is an intravenously administered antiplatelet agent that could be used alone or in conjunction with thrombolytic therapy to treat patients with acute ischemic stroke. However, experience with medication for treatment of patients with stroke is limited. Symptomatic intracranial bleeding is the most common serious complication of therapies that aim at restoring or improving blood flow to the brain after stroke and it is the most likely potential serious complication of the use of abciximab in this setting. Preliminary data suggest that abciximab is not associated with a prohibitively high rate of symptomatic intracranial hemorrhage. Further research is needed to determine the safety and potential efficacy of abciximab for treatment of ischemic stroke.
Details
- Title: Subtitle
- Potential role of abciximab in ischemic cerebrovascular disease
- Creators
- James M Winkley - Division of Cerebrovascular Diseases, Department of Neurology, University of Iowa College of Medicine, Iowa City, Iowa, USAHarold P Adams - Division of Cerebrovascular Diseases, Department of Neurology, University of Iowa College of Medicine, Iowa City, Iowa, USA
- Resource Type
- Journal article
- Publication Details
- The American journal of cardiology, Vol.85(8), pp.47-51
- Publisher
- Elsevier Inc
- DOI
- 10.1016/S0002-9149(00)00878-X
- PMID
- 10793180
- ISSN
- 0002-9149
- eISSN
- 1879-1913
- Language
- English
- Date published
- 2000
- Academic Unit
- Neurology; Iowa Neuroscience Institute
- Record Identifier
- 9984020873902771
Metrics
8 Record Views